Abnormal signaling through receptor tyrosine kinase (RTK) moieties plays a crucial role in colon cancer tumorigenesis. Wild type KIT (WT-KIT), a RTK that is activated upon binding with stem cell factor (SCF), is highly expressed in a subset of colorectal cancers (CRCs). We found that activated WT-KIT gradually decreased through lysosomal degradation after SCF binding. We demonstrated that PKC-δ binds to WT-KIT and is involved in KIT recycling. We also demonstrated that expression of WT-KIT and activated PKC-δ are concomitantly present in some CRC tissues, and KIT expression correlates with poor patient survival. Our findings suggest that sustained WT-KIT activation through PKC-δ-mediated WT-KIT recycling may contribute to rapid CRC progression, and provides a rationale for anti-KIT therapy in a subset of CRCs with WT-KIT expression. 
Introduction
The genetic aberrations of colon cancers have been well characterized. Recent colon cancer genome analysis studies demonstrated that most colorectal cancers show similar patterns of genomic alteration, and mutations of APC, TP53, SMAD4, PIK3CA and KRAS were frequently identified (1) . These mutations contribute to the development of biologically aggressive colorectal carcinomas and are directly linked to dysregulation of signaling pathways involving Wnt/β-catenin, PI3K, and MAPK in colon cancers (2) .
Among the signaling pathways that are active in colorectal cancers (CRCs), activation of signaling through the receptor tyrosine kinase (RTK) moieties of growth factor receptors plays a crucial role in colon cancer tumorigenesis and drug targeting. Activation of epidermal growth factor receptor (EGFR) is particularly relevant in CRCs. EGFR overexpression occurs in 60 to 80% of CRCs and Cetuximab, a monoclonal antibody to EGFR, has been shown to be clinically effective in CRCs (3) . KIT is a RTK that is expressed in some epithelial cell lineages during embryogenesis. KIT and its ligand, stem cell factor (SCF), are essential for the maturation of some primitive cells during embryonic development and aberrant expression of KIT and SCF has been reported in human malignant tumor cells derived from epithelial cell lineages that express KIT during embryogenesis such as breast, lung, and prostate (4-6). In addition, previous studies demonstrated that some human CRCs express high levels of KIT and SCF relative to normal mucosa cells (7, 8) .
Activation of KIT in tumors is achieved in two different ways. Activation through the acquisition of activating mutations is common and has been reported in gastrointestinal stromal tumor (GIST), acute myelogenous leukemia (AML), and mastocytosis (4) . The molecular mechanisms of this type of activation are well established and imatinib, which targets activated KIT molecules, is effective in the control of tumors with KIT mutations (9, 10) . The other pathway involves ligand-dependent activation of wild type KIT (WT-KIT). To date, SCF is the only identified ligand that binds to KIT. Binding of SCF to WT-KIT leads to receptor dimerization and induces activation of downstream signals (11, 12) . Although the molecular characteristics of KIT activation after SCF binding are well established, little is known about the functional roles of SCF-induced WT-KIT activation in cancers.
In this study, we analyzed the biological alteration of KIT after SCF binding in WT-KIT expressing colorectal cancer cells as well as its impact on downstream signaling. Based on our findings, we propose that sustained activation of downstream signals after KIT and SCF binding can be accomplished by PKC-δ-mediated recycling of WT-KIT.
Materials and Methods
Research. were purchased from American Type Culture Collection (ATCC). GIST882 was previously reported (13) . DLD-1, HCT116, SNUC4, Colo320DM, and Ls174T were selected from 11 colon cancer cell lines after initial screening of KIT expression by reverse transcriptionpolymerase chain reaction (RT-PCR). DLD-1, Colo320DM, and Ls174T cells were selected as KIT-expressing colon cancer cell lines, while HCT116 and SNUC4 cells were selected as control cell lines lacking KIT expression. In addition, the GIST882 cell line (derived from gastrointestinal stromal tumor with KIT-K642E mutation) was used as a positive control; HeLa cells were used as a negative control for KIT expression.
Construction of expression vectors
An expression vector for KIT cDNA containing a FLAG tag was constructed using pCMV vector and KIT coding regions amplified by PCR using cDNA from DLD-1 cells. The cDNA of Rab-11 was amplified from HEK293 cells, and was constructed using the same method as that for the KIT expression vector. The generation of PKC constructs was described previously (14) .
Western blotting and immunoprecipitation
Whole cell lysates were prepared using passive lysis buffer (Promega, Madison, WI, USA) with a protease inhibitor cocktail (Roche, Meylan, France). The membranes were incubated with primary antibodies against GAPDH (Trevigen, Gaithersburg, MD, USA); FLAG (SigmaAldrich, Poole, Dorset, UK); KIT (Dako, Cambridge, UK); ERK, phospho-ERK, HA, (Santa Cruz Biotechnology, Santa Cruz, CA, USA); phospho-KIT (Invitrogen); and AKT, phospho-AKT, PKC-δ, phospho-PKC-δ (Cell Signaling, Danvers, MA, USA) for 2 hours at room temperature. Western blot images were analyzed with a LAS-4000 Mini camera (Fujifilm, Tokyo, Japan). For immunoprecipitation, lysates were precleared and immunoprecipitated with anti-FLAG M2-agarose affinity gel (Sigma-Aldrich) at 4°C.
Immunofluorescence
Cells grown on slides were rinsed with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde for 15 minutes, and permeabilized in 0.3% Triton X-100 in PBS. The slides were incubated with primary antibody for 1 hour and incubated for 50 minutes with the appropriate fluorescent-labeled secondary antibody (Invitrogen). All images were obtained 6 using a LSM700 confocal microscope (Carl Zeiss, Jena, Germany).
Quantitative RT-PCR
RT-PCR was performed using AmpliTaq Gold® 360 DNA Polymerase (Applied Biosystems, Foster City, CA, USA). The qRT-PCR was performed using the ABI PRISM 7500 Sequence Detector (Applied Biosystems) and SYBR Premix Ex Taq II (TaKaRa, Tokyo, Japan). The amount of target mRNA was normalized to that of GAPDH mRNA. The sequences of the primers used are listed in Supplementary Table S1 .
Cell proliferation assay
DLD-1 cells expressing KIT were washed with PBS, and incubated with cell media containing imatinib (50 uM), as well as SCF (50 ng/mL) and/or PMA (300 nM). The number of cells was manually counted 3 days after the drug treatment, and the morphology of the cells was examined under a microscope. Every experiment was independently conducted in triplicate, and the mean number was used for further analysis.
Cell invasion assay
Cell invasion assay was performed using the Chemicon QCM Cell Invasion Assay Kit 
FACS analysis
Colo320DM and DLD-1 cells treated with SCF and/or PMA were detached using 5 mM 
Statistical analysis
The survival rate of colon cancer patients according to KIT expression was analyzed by the Kaplan-Meier method, and differences between groups were evaluated by the log-rank test.
Pearson's Chi-square tests were used for comparison of KIT expression and relevant clinicopathological parameters. Student's t-tests were performed to analyze continuous data.
All tests were two-tailed. All p-values <0.05 were considered significant.
Results

Identification of WT-KIT expression in colon cancer cell lines
We examined KIT expression in two control cell lines (GIST882 as a positive control and HeLa as a negative control) and five colon cancer cell lines (DLD-1, HCT116, SNUC4, Colo320DM, and Ls174T). KIT mRNA expression was identified in three CRC cell lines (DLD-1, Colo320DM, and Ls174T) by RT-PCR, qRT-PCR and KIT protein expression in these three cell lines correlated with the mRNA levels (Fig. 1A) . No mutations were found in exons 9, 11, 13, and 17, which are sites of previously identified KIT mutations (data not shown). Loss of KIT expression following treatment with KIT-specific siRNA was confirmed (Fig. 1B) . These findings indicate that WT-KIT is strongly expressed in a subset of CRC cell lines.
SCF induces KIT activation and subsequently activates AKT and ERK signaling pathways
We next examined whether WT-KIT is activated after SCF treatment of DLD-1, Colo320DM, and Ls174T cell lines. In all three cell lines, treatment with SCF induced KIT activation in a dose-dependent manner. SCF also induced activation of the well-known downstream molecules AKT and ERK that are related to cell survival and proliferation, respectively, as assessed by Western blotting measuring the phosphorylated forms of these proteins ( Fig.   1C and Supplementary Fig. S1 ). Activation of AKT and ERK after SCF treatment was abolished by KIT siRNA, demonstrating that activation of AKT and ERK is dependent on activated KIT (Fig. 1C) . In contrast to the cell lines with WT-KIT expression, SCF treatment did not affect downstream signaling pathways in GIST882 (KIT-K642E-mutant GIST) and HMC-1 (KIT-D816V-mutant mast cell leukemia) cells that express mutant KIT ( Supplementary Fig. S2 ). These findings confirm that SCF activates WT-KIT and downstream signaling pathways in colon cancer cell lines but has no effect on mutant KIT expressed in other cell lines. We next evaluated the time course of SCF stimulation by examining the status of KIT activation 5 and 15 minutes after SCF treatment and found that levels of phospho-KIT (p-KIT), phospho-AKT (p-AKT), and phospho-ERK (p-ERK) gradually increased over this period (Fig. 1D) . However, the expression of KIT was markedly decreased 15 minutes after SCF treatment ( Fig. 1D and Supplementary Fig. S3 )
Activated KIT proteins are degraded by the lysosomal degradation pathway
Having demonstrated down-regulation of WT-KIT protein 15 minutes after SCF treatment, we measured the mRNA and protein levels of KIT during a 2-hour period after SCF treatment. KIT mRNA expression levels in DLD-1, Colo320DM, and Ls174T cell lines were constant during this time whereas the levels of KIT protein were markedly decreased at 1 hour after SCF treatment ( Fig. 2A) . Also FACS analysis of KIT after SCF treatment showed that the proportion of tumor cells expressing KIT decreased from 50.9% to 21.6% after SCF treatment ( Supplementary Fig. S4 ). The expression of p-KIT was markedly increased 10 minutes after SCF treatment, but was barely detectable at 1 and 2 hours ( Fig. 2A) . In contrast to the gradual down-regulation of WT-KIT proteins after SCF treatment, there was no change in the expression of mutant KIT or p-KIT proteins in GIST882 and HMC-1 cells ( Supplementary Fig. S5 ).
It is well known that RTKs are internalized into vesicles and transferred via early and late endosomes for degradation in the lysosome upon the appropriate stimulus. Normally, this endocytotic process is constantly ongoing in the cell. To confirm whether lysosomal degradation is responsible for the gradual decrease in WT-KIT after SCF binding, we designed a rescue assay using inhibitors known to block two major protein degradation pathways: Bafilomycin A1 was used to block lysosomal degradation and MG132 was used to block the proteasomal pathway. Cells were treated with SCF alone or respective inhibitors for 1 hour and expression of KIT protein were analyzed. The results showed that KIT proteins were barely rescued after inhibition of proteasomal degradation (Fig. 2B) , whereas there was significant rescue of KIT protein (up to 100% compared to the control) after Bafilomycin A1 treatment, indicating that the down-regulation of activated WT-KIT is mainly dependent on the lysosomal degradation pathway. Additionally, we also found that p-AKT and p-ERK levels also increased after Bafilomycin A1 treatment (Fig. 2C) . We next validated the lysosomal degradation of KIT by analyzing the intracellular location of KIT after SCF binding. In the resting state, KIT proteins were mainly distributed on the plasma membrane of DLD-1 cells. After SCF stimulation, rapid internalization of KIT was observed (Fig. 2D) . To identify the location of KIT after SCF stimulation, we compared the localization of KIT and an endosome marker LAMP-1 (lysosomal associated membrane protein 1). Without SCF stimulation, KIT was rarely co-localized with LAMP-1; however, the majority of KIT proteins clearly showed co-localization with LAMP-1 in cells treated with SCF (Fig. 2D) . Taken together, these findings indicate that WT-KIT is activated by SCF binding, internalized, and finally targeted to the lysosomes for degradation.
PKC activation rescues KIT from lysosomal degradation
Given the rapid degradation of WT-KIT in colon cancer cell lines after SCF treatment, we speculated on the roles of SCF-KIT activation in CRC tumorigenesis. If SCF-KIT activation plays an important role in CRC tumorigenesis, constant activation of SCF-KIT would be required. Because WT-KIT proteins are degraded in the lysosome after binding of SCF, we hypothesized that activated WT-KIT proteins are recycled in tumor cells and thus constantly contribute to CRC tumorigenesis. We further suspected that protein kinase C (PKC) activation might be involved in the recycling of WT-KIT protein because it has been reported that other RTK receptors such as EGFR and platelet-derived growth factor (PDGF) β-receptor are recycled by PKC activation (15, 16) . To test the involvement of PKC in the regulation of KIT, we treated the three KIT-expressing cell lines with phorbol 12-myristate 13-acetate (PMA), a PKC activation factor, after SCF activation. We found that the level of KIT proteins was dramatically rescued after PMA treatment, and that activated forms of KIT, AKT, and ERK were stabilized even 2 hours after SCF treatment in all three cell lines (Fig. 3A) .
When DLD-1 and Colo320DM cells were concomitantly treated with PMA and Gö6983, a PKC inhibitor, KIT and p-KIT were no longer stabilized (Fig. 3B) . We additionally performed 
stimulation, cytoplasmic translocation of KIT was evident and only a scant amount of KIT was present in the plasma membrane. When the cells were concomitantly treated with SCF and PMA, more KIT protein was detected on the plasma membrane than in cells treated with SCF only, suggesting that PMA-mediated PKC activation leads to recycling of KIT proteins.
In addition, we observed very little co-localization of KIT proteins with LAMP-1 in the cells co-treated with SCF and PMA (Fig. 3C) . To validate the endosomal recycling of KIT after PMA stimulation, we analyzed the co-localization of KIT and Rab11, a well-known recycling endosome marker. When Ls174T cells were treated with SCF alone, very little colocalization of Rab11 and KIT was identified; however, in cells treated concomitantly with SCF and PMA, a large proportion of KIT proteins co-localized with Rab11 (Fig. 3D) . We performed additional FACS analysis to confirm the mediation of KIT recycling by Rab11. To do so, we evaluated membranous KIT expression by FACS after transfection of wild-type form (Rab11-WT) or dominant negative form of Rab11 (Rab11-S25N) in DLD-1 cells. We found rare recycle of KIT in DLD-1 cells transfected with the dominant negative form of Rab11, compared to the wild-type form of Rab11 transfection (Supplementary Fig. S7 ).
These findings indicate that PKC activation plays a role in sustained KIT activation by inhibiting KIT degradation and instead recycling the KIT proteins.
PKC-δ directly binds and rescues WT-KIT
Having identified a role of PKC in constant SCF-KIT activation in colon cancer cells, we investigated which isoform of PKC contributes to KIT recycling by immunoprecipitation assays using synthetic KIT and PKC proteins. In vitro binding assays performed after treatment with SCF and PMA showed that WT-KIT directly and exclusively binds to PKC-δ (Fig. 4A) . To further examine the interaction between KIT and PKC-δ, we performed binding assays in the presence or absence of SCF and/or PMA. Binding of KIT to PKC-δ was only observed after treatment with both SCF and PMA, indicating that activated PKC-δ is involved in KIT recycling (Fig. 4B) . Interestingly, the localization of KIT and PKC-δ was exclusively SCF and PMA dependent; no co-localization between KIT and PKC-δ was found in cells treated with SCF or PMA alone (Fig. 4C) . To confirm that activation of PKC-δ can rescue KIT, cells were transfected with control siRNA or PKC-δ-specific siRNA before treatment with SCF and PMA. The rescue of KIT was substantially reduced from 61% to 8% in the cells transfected with siPKC-δ compared with control cells (Fig. 4D) , indicating that KIT recycling depends on activated PKC-δ.
PKC activation enhances colon cancer cell proliferation and invasion
Research. In order to evaluate the tumorigenesis effects of PKC activation in KIT expressing colon cancer cells, we chose one KIT expressing colon cancer cell line (DLD-1), in which to perform a cell proliferation and invasion assay after 3 days with or without PKC activation.
Treatment of SCF and PMA induced p-KIT, p-AKT, and p-ERK expression. The increased expressions of p-KIT and p-AKT were mostly inhibited by imatinib, while the expression of p-ERK was rarely inhibited (Supplementary Fig. S8 ). We next evaluated the inhibitory effects of imatinib on proliferation and invasion of CRC cells. When the cells were co-treated with SCF and PMA, a marked increase (64% increase compared to the control) in tumor cell number was recorded. Treatment of imatinib in cells treated with SCF and PMA reduced the number of tumor cells (Supplementary Fig. S9A ). In the cell invasion assay, DLD-1 cells treated with SCF and PMA exhibited greater cell invasion than the control cells. However, the addition of imatinib to the cells co-treated with SCF and PMA dramatically reduced cell invasion. Knockdown of KIT also markedly blocked the invasion ability of DLD-1 cells (Supplementary Fig. S9B ).
KIT and PKC-δ are activated in KIT-expressing colon cancer tissues
Although the expression of KIT in colon cancer cell lines has previously been reported, KIT expression in colon cancer tissues was not well characterized. We evaluated KIT expression in 250 CRC tissues by immunohistochemistry and detected expression in 47 (18.8%) cases.
In Western blot analysis of 22 of the 47 KIT-immunopositive cases, 18 cases (81.8%) showed strong KIT expression compared with the normal matched mucosa (Fig. 5A) . In contrast, Western blotting did not show increased KIT expression in 10 KIT-immunonegative colon cancers (data not shown). We also demonstrated that most of the KIT protein expressed in colon cancer tissues is activated by detecting p-KIT expression in 16 of the 22 KIT-immunopositive colon tissues (72.7%). The expression of KIT and activated KIT in tumor tissues was significantly higher than in normal tissue ( Fig. 5B and C) . Additionally, the expression of phospho-PKC-δ (p-PKC-δ) was increased in the CRC tissues with KIT expression and there was a linear correlation between KIT expression and p-PKC-δ expression (Pearson r=.5119, Spearman r =.445, P<.001; Fig. 5D ).
Clinicopathologic characteristics of colon cancers with KIT expression
Lastly, we analyzed the clinicopathologic characteristics of CRCs with KIT expression among 250 CRCs using tissue microarray. Expression of KIT was not identified in normal colonic mucosa and most of the CRCs tested. The majority of tumors with KIT expression showed expression in the tumor cell cytoplasm (Fig. 6A) Bethesda, MD), and categorized as KIT expression or no expression (Fig. 6B) . The clinicopathologic characteristics of the 250 patients with CRCs according to KIT expression are described in Supplementary Table S2 . No significant correlation between KIT expression and clinicopathologic variables was found except for increased serum CEA level in CRCs with KIT expression (Supplementary Table S2 ). We also evaluated KIT as a prognostic factor and found that the expression of KIT correlated with poor survival. The overall cumulative survival rates for patients with KIT expression (n=47) and without KIT expression (n=203) were 68.1 and 85.7%, respectively (P=.004; Fig. 6C ). When we analyzed the correlation between KIT expression and patient survival for the subgroup of patients with stage II and III disease, the overall cumulative survival rates for stage II and III patients with KIT expression (n=34) and without KIT expression (n=161) were 79.4% and 92.5%, respectively (P=.017, Fig. 6D ).
Discussion
KIT, a member of the RTK family, is a highly oncogenic tyrosine kinase that is involved in the activation of major signal transduction pathways. The best-known downstream signal transduction pathways of KIT are PI3 kinase-AKT, Ras-ERK, and JAK-STAT (11, 17, 18 ). As we have described previously, KIT can be activated in two ways: WT-KIT is activated by binding of SCF whereas mutant KIT is constantly activated in the absence of SCF (11, 18, 19) .
Although expression of WT-KIT has been reported in many tumors, including CRCs (7, (19) (20) (21) , its role in tumorigenesis and the therapeutic efficacy of inhibition of activated KIT have not been well characterized. If activated WT-KIT plays a role in tumorigenesis, it is reasonable to assume that the downstream signaling pathway of activated WT-KIT would be the same or similar to that of mutant KIT and the activation would be constant, as for mutant KIT. SCF is the only known ligand for WT-KIT (18) . To achieve the constant activation of the signaling pathway from WT-KIT, continuous stimulation of SCF is necessary. As reported in previous studies, exogenous SCF facilitates tumor growth and angiogenesis (22) , and expression of SCF is up-regulated by hypoxia in breast cancer cells (23) . We found absent or very low levels of SCF mRNA in three CRC cell lines with KIT expression ( Supplementary   Fig. S10) . Accordingly, the sources of SCF in CRCs are expected to be diverse, and continuous SCF stimulation can be achieved in some specific tumor environments. The present study demonstrated that the signaling pathways downstream of the activation of WT-KIT after SCF binding are almost the same as those activated through mutant KIT (11, 19) Research. 
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and that imatinib exerts anti-proliferative and anti-invasive effects (19, 24) . Nevertheless, WT-KIT degradation after SCF binding has been reported (25) . Therefore, continuous SCF stimulation in tumor cells and activation of an intracellular mechanism for the inhibition of WT-KIT degradation may be required for WT-KIT mediated tumorigenesis in CRCs with KIT expression.
In this study, we provide the first evidence that WT-KIT can be constantly activated through recycling of KIT. When we continuously stimulated KIT-expressing cell lines with SCF, the expression of KIT decreased according to the time of SCF treatment and activation of the downstream signaling pathways was also decreased. Although these findings suggest a physiological role of WT-KIT activation, they raise questions regarding the role of SCF-KIT activation in tumorigenesis. Although we observed degradation of activated KIT in colon cancer cell lines, we hypothesized that KIT could be recycled in the tumor cells and thus be continuously active after SCF treatment. Some other RTKs are known to be rapidly recycled back to the membrane in cancer cells instead of being degraded. For example, activation of PKC-α is a critical step in sorting the PDGF β-receptor towards Rab4a-dependent recycling (16) . Recent studies also suggest that recycling of PDGFR drives the invasion of glioblastoma cells, and recycling of EGFR coupled with α5β1 integrin induces the migration of ovarian cancer cells (26, 27) . However, little is known about recycling of KIT and the impact of KIT-SCF activation on colorectal cancer progression. We therefore investigated the possibility that KIT is recycled in KIT-expressing colon cancer cell lines. In the case of EGFR recycling, PKC is known to be involved in the inhibition of EGFR degradation (15) . We initially activated PKC by treating colon cancer cells with PMA and found that KIT was not degraded after prolonged SCF stimulation but instead constantly activated the downstream signaling pathways. These findings indicate that KIT-SCF might contribute to colon cancer tumorigenesis through PKC activation and subsequent KIT recycling. We further demonstrated that PKC-δ is responsible for KIT recycling by showing direct binding of KIT and PKC-δ in vitro and concomitant overexpression of KIT and PKC-δ in a subset of colon cancer tissues. PKCs play important roles in the regulation of proliferation, tumor promotion, apoptosis, and angiogenesis (28, 29) . Various factors such as growth factors, tumor promoters, chemotherapeutic agents, and ras protein induce activation of PKCs (30) (31) (32) .
Activation of PKC-δ by substance P-induced proinflammatory signaling in human colonocytes (33) and by a hypoxic microenvironment has been reported (34) . Therefore, it is likely that endogenous PKC-δ is activated and functions in KIT recycling in the microenvironment of CRCs. Our findings indicate that CRCs expressing WT-KIT can constantly generate activated SCF-KIT signaling as a result of KIT recycling ( Supplementary   Fig.S11 ). In addition to demonstrating expression of endogenous KIT and activated PKC-δ in CRCs tissues, we found that colon cancer patients with KIT-expressing tumors showed a worse prognosis than patients without KIT expression. One previous report also showed worse prognostic correlation with KIT expression in colon cancers (35) , but several studies found no prognostic correlations (36, 37) . These findings might result from the variable and low 
